Faiz Ali Khan

Dr. Faiz Ali Khan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FKFaiz Ali Khan
Faiz Ali Khan
NFNa Fang
Na Fang
WZWeijuan Zhang
Weijuan Zhang
SJShaoping Ji
Shaoping Ji
RNA-binding proteins (RBPs) modulate the expression level of several target RNAs (such as mRNAs) post-transcriptionally through interactions with unique binding sites in the 3′-untranslated region. There is mounting information that suggests RBP dysregulation plays a significant role in carcinogenesis. However, the function of FMR1 autosomal homolog 1(FXR1) in malignancies is just beginning to be unveiled. Due to the diversity of their RNA-binding domains and functional adaptability, FXR1 can regulate diverse transcript processing. Changes in FXR1 interaction with RNA networks have been linked to the emergence of cancer, although the theoretical framework defining these alterations in interaction is insufficient. Alteration in FXR1 expression or localization has been linked to the mRNAs of cancer suppressor genes, cancer-causing genes, and genes involved in genomic expression stability. In particular, FXR1-mediated gene regulation involves in several cellular phenomena related to cancer growth, metastasis, epithelial-mesenchymal transition, senescence, apoptosis, and angiogenesis. FXR1 dysregulation has been implicated in diverse cancer types, suggesting its diagnostic and therapeutic potential. However, the molecular mechanisms and biological effects of FXR1 regulation in cancer have yet to be understood. This review highlights the current knowledge of FXR1 expression and function in various cancer situations, emphasizing its functional variety and complexity. We further address the challenges and opportunities of targeting FXR1 for cancer diagnosis and treatment and propose future directions for FXR1 research in oncology. This work intends to provide an in-depth review of FXR1 as an emerging oncotarget with multiple roles and implications in cancer biology and therapy.

5 June 2024 in Cancer Gene Therapy
Verified
Journal Article
Closed access
PDF file
FKFaiz Ali Khan
Faiz Ali Khan
BNBernard Nsengimana
Bernard Nsengimana
UAUsman Ayub Awan
Usman Ayub Awan
XJXin-Ying Ji
Xin-Ying Ji
SJShaoping Ji
Shaoping Ji
JDJingcheng Dong
Jingcheng Dong

15 July 2019 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
MRMuhammad Usman Rashid
Muhammad Usman Rashid
FKFaiz Ali Khan
Faiz Ali Khan
Noor MuhammadNoor Muhammad
Noor Muhammad
ALAsif Loya
Asif Loya
UHUte Hamann
Ute Hamann
Partner and localizer of BRCA2 (PALB2) is a breast cancer susceptibility gene that plays an important role in DNA repair. This is the first study assessing the prevalence of PALB2 mutations in early-onset and familial breast/ovarian cancer patients from Pakistan. PALB2 mutation screening was performed in 370 Pakistani patients with early-onset and familial breast/ovarian cancer, who were negative for BRCA1, BRCA2, TP53, CHEK2, and RAD51C mutations, using denaturing high-performance liquid chromatography analysis. Mutations were confirmed by DNA sequencing. Novel PALB2 alterations were analyzed for their potential effect on protein function or splicing using various in silico prediction tools. Three-hundred and seventy-two healthy controls were screened for the presence of the identified (potentially) functional mutations. A novel nonsense mutation, p.Y743*, was identified in one familial breast cancer patient (1/127, 0.8%). Besides, four in silico-predicted potentially functional mutations including three missense mutations and one 5' untranslated region mutation were identified: p.D498Y, novel p.G644R, novel p.E744K, and novel c.-134_-133delTCinsGGGT. The mutations p.Y743* and p.D498Y were identified in two familial patients diagnosed with unilateral or synchronous bilateral breast cancer at the ages of 29 and 39, respectively. The other mutations were identified in an early-onset (≤ 30 years of age) breast cancer patient each. All five mutations were absent in 372 healthy controls suggesting that they are disease associated. Our findings show that PALB2 mutations account for a small proportion of early-onset and hereditary breast/ovarian cancer cases in Pakistan.

20 October 2022 in Gene & Protein in Disease
Verified
Journal Article
Open access
PDF file
FKFaiz Ali Khan
Faiz Ali Khan
BNBernard Nsengimana
Bernard Nsengimana
NKNazeer Khan
Nazeer Khan
JHJingjing Huang
Jingjing Huang
HGHaojie Guo
Haojie Guo
SJShaoping Ji
Shaoping Ji
Since decades ago, circular RNAs (circRNAs) have been known for their critical role in RNA maturation, RNA transportation, epigenetic regulation, gene transcription, peptide/protein translation, and interaction with proteins to modulate their activities. At present, circRNAs are being extensively studied as oncotargets in the onset and development of several malignancies and treatment resistance by modulating various signaling pathways and cellular processes such as ubiquitination, degradation, invasion, proliferation, c-Myc oncoprotein stabilization, epithelial-mesenchymal transition, autophagy, and apoptosis. In addition, circRNAs are known to be highly conserved, have a longer life span than other RNAs, and their differential expressions are implicated in solid tumors and hematological malignancies. However, their potential diagnostic and therapeutic targets are not fully elucidated. Therefore, we sought to underline the opportunities and constraints associated with using these oncotargets in cancer therapy by outlining the functional mechanisms of circRNAs and their ectopic expression in distinct malignancies. The clinical applications of circRNAs in developing progressive markers like liquid biopsy biomarkers and for treating cancers are also prospected in this paper.

5 February 2025 in Gene & Protein in Disease
Verified
Journal Article
Open access
PDF file
FKFaiz Ali Khan
Faiz Ali Khan
XJXin-Ying Ji
Xin-Ying Ji
SJShaoping Ji
Shaoping Ji
JDJingcheng Dong
Jingcheng Dong
Post-transcriptional regulation by RNA-binding proteins (RBPs) is critical for mRNA stability, localization, and translation, primarily through interaction with the 3’-untranslated region. Dysregulation of RBPs has been associated with various cancers, with fragile X-related protein 1 (FXR1) emerging as a critical RBP involved in tumorigenesis through its interactions with target mRNAs. Despite its significance, the specific role of FXRI in cancer progression remains underexplored. In this study, we investigated FXR1’s function using SH-SY5Y cells. RNA immunoprecipitation (RNA-IP) assay was employed to isolate RNA complexes associated with FXR1. We generated stable cell lines with either FXR1 overexpression or silencing to assess the impact of FXRI binding to mRNA complexes. Subsequent analyses, including quantitative reverse transcription polymerase chain reaction, correlation analysis, gene expression profiling, and survival analysis, were performed to validate the interactions of FXR1 with target mRNAs. Our RNA-IP analysis identified several mRNAs significantly enriched in FXR1-bound RNA complexes, including SHISAL1, SLC43A3, NBAT1, PDZK1IP1, ACKR3, KCNN3, NECAB2, ANO5, ATOH8, IGFBP7, LEMD1, GPR35, WNT7A, and F2RL3. Notably, we observed changes in the expression levels of these genes following FXR1 overexpression or depletion, indicating FXR1-mediated functional regulation. Co-expression analysis further supported FXR1’s association with these target mRNAs. These findings highlight the significant role of FXR1 in regulating the stability and expression of key mRNAs implicated in malignancies. The dysregulation of FXR1 and its interaction with these target transcripts suggest that FXR1 plays a critical role in tumor biology, potentially offering new avenues for therapeutic interventions. This study provides a deeper understanding of FXR1’s involvement in cancer and underscores the importance of RBPs in the post-transcriptional regulatory landscape of cancer progression.

12 January 2025 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
FKFaiz Ali Khan
Faiz Ali Khan
DFDalia Fouad
Dalia Fouad
FAFarid Ataya
Farid Ataya
USUmar Saeed
Umar Saeed
XJXin-Ying Ji
Xin-Ying Ji
JDJingcheng Dong
Jingcheng Dong
Mitochondrial ribosomal protein S23 (MRPS23), encoded by a nuclear gene, is a well-known driver of proliferation in cancer. It participates in mitochondrial protein translation, and its expression association has been explored in many types of cancer. However, MRPS23 expression associations are rarely reported in breast cancer (BC). In this study, we explored the MRPS23 expression in BC cells compared with the non-tumoral breast cells. Overexpression and knockdown analysis of MRPS23 were performed in BC cells. Transfection efficiency was evaluated by western blot and qRT-PCR analysis. The role of MRPS23 in the malignant biological behaviors of BC cells was investigated using in-vitro experiments. Our results demonstrate that MRPS23 was aberrantly overexpressed at both the transcript and protein levels in BC cells. Additional findings reveal that deficiency of MRPS23 is associated with a decrease in cell proliferation/viability and compromised cell migration/invasion in BC cells. Relative to the sh-Ctrl group, the expression levels of cadherin, SNAI 1, and TWIST 1 decreased in the MRPS23 knockdown BC cells. We further found a significant decrease in the expression levels of Cyclin D1, Axin 2, LEF1, NKD1, and Survivin in MRPS23 knockdown cells. In conclusion, we found an association between MRPS23 knockdown and the metastasis ability of BC cells. These findings reveal that MRPS23 significantly decreases the migration and invasion of BC, thus inhibiting BC progression. We confirmed for the first time that MRPS23 expression determines the metastasis features of BC. Hence, the findings justify the key role of this protein in BC progression; therefore, it may be a potential therapeutic target for BC therapy.